Research map: Oral Hypoglycemic Therapy in Metabolic Dysfunction-Associated Fatty Liver Disease

Back to the article

Papers in this map

  1. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial · John Dormandy · 2005 · 4156 citations · Cited by this paper
  2. Risk factors of advanced fibrosis in non-alcoholic fatty liver disease, associated with type 2 diabetes mellitus · 2026 · Related
  3. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis · Arun Jayant Sanyal · 2010 · 3352 citations · Cited by this paper
  4. A clinical case of liver fibrosis in type 1 diabetes mellitus · 2026 · Related
  5. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review · Zobair M. Younossi · 2023 · 3310 citations · Cited by this paper
  6. The relationship of vitamin D-binding protein with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus · 2026 · Related
  7. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease · Mary Eugenia Rinella · 2023 · 2555 citations · Cited by this paper
  8. The evolution of concepts of inflammatory bowel diseases in children (literature review) · 2026 · Related
  9. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) · Melanie J. Davies · 2022 · 2106 citations · Cited by this paper
  10. Factors influencing the formation of the intestinal microbiota of a newborn (literature review) · 2026 · Related
  11. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis · Renata Belfort · 2006 · 1832 citations · Cited by this paper
  12. Gastrointestinal manifestations and eating behavior in autism spectrum disorder: the role of sensory dysfunction and intestinal microbiota · 2026 · Related
  13. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease · Arun Jayant Sanyal · 2021 · 1134 citations · Cited by this paper
  14. The work of the registry of precancerous diseases is a real way of primary prevention of stomach cancer · 2026 · Related
  15. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack · Walter N. Kernan · 2016 · 1124 citations · Cited by this paper
  16. Drug-induced liver injury associated with albendazole: a literature review and own clinical case of acute hepatitis C with liver failure in a 9-year-old child · 2026 · Related
  17. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus · Kenneth J. Cusi · 2016 · 1018 citations · Cited by this paper
  18. Clinical and pathophysiological aspects of the development of chronic gastrointestinal diseases as predictors of overall aging · 2026 · Related
  19. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings · Kenneth J. Cusi · 2022 · 1009 citations · Cited by this paper
  20. Chronic constipation in a comorbid patient - the place of lactulose in the therapy of a complex patient · 2026 · Related
  21. Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin · Jan Bolinder · 2012 · 878 citations · Cited by this paper
  22. Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes · Steven E. Nissen · 2008 · 853 citations · Cited by this paper
  23. Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance · Ralph A. DeFronzo · 2011 · 752 citations · Cited by this paper
  24. Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis · Guruprasad Padur Aithal · 2008 · 713 citations · Cited by this paper
  25. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association · P. Barton Duell · 2022 · 700 citations · Cited by this paper
  26. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. · S Aronoff · 2000 · 632 citations · Cited by this paper
  27. Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial · Vlad Ratziu · 2008 · 627 citations · Cited by this paper
  28. A global view of the interplay between non-alcoholic fatty liver disease and diabetes · Norbert Stefan · 2022 · 562 citations · Cited by this paper
  29. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options · Amalia Gastaldelli · 2019 · 452 citations · Cited by this paper
  30. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis · Giovanni Musso · 2017 · 442 citations · Cited by this paper
  31. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study · Jan W. Eriksson · 2018 · 395 citations · Cited by this paper
  32. Thiazolidinediones: the Forgotten Diabetes Medications · Harold E. Lebovitz · 2019 · 390 citations · Cited by this paper
  33. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial · SABINE KAHL · 2019 · 358 citations · Cited by this paper
  34. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes · James D. Lewis · 2015 · 323 citations · Cited by this paper
  35. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial · Fernando Bril · 2019 · 315 citations · Cited by this paper
  36. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial · Olga Vaccaro · 2017 · 297 citations · Cited by this paper
  37. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients · Aino Latva‐Rasku · 2019 · 253 citations · Cited by this paper
  38. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes · Ralph A. DeFronzo · 2019 · 224 citations · Cited by this paper
  39. Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications · Sunder Raj D. Mudaliar · 2003 · 209 citations · Cited by this paper

Source: OpenAlex (CC0)